Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 10, 2016. The report serves as a notification of transactions involving directors, persons discharging managerial responsibilities, or connected persons, specifically regarding changes in share interests.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of a specific executive transaction rather than a financial performance report.
Material Changes
The filing details a change in the shareholding of Mr. Philip Thomson, a Person Discharging Managerial Responsibilities. On May 9, 2016, Mr. Thomson exercised nil cost options over 1,087 and 411 ordinary shares granted on February 28, 2013, which vested on February 28, 2016, under the GlaxoSmithKline Deferred Annual Bonus Plan.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of the share transaction details.
Important Facts for Investors
- Executive Transaction: Mr. Philip Thomson exercised options on 1,087 and 411 shares.
- Settlement Method: The company delivered the net-of-tax value in shares, totaling 778 shares.
- Share Price: The fair market value of an ordinary share at the time of exercise was £14.53 and £14.54 respectively.
- Notification Date: The company and Mr. Thomson were advised of these transactions on May 10, 2016.